What second line treatment would you choose for a post menopausal woman with HR+ HER2+ metastatic breast cancer with low burden disease treated with first line aromatase inhibitor and trastuzumab?
Answer from: Medical Oncologist at Academic Institution
The TAnDEM trial did prove that triple-positive metastatic breast cancer should be treated with both anti-HER2 therapy and endocrine therapy. Although there is no direct data in the setting of the above-described case to my knowledge, we can extrapolate from the large body of evidence that exists fo...
Comments
Medical Oncologist at Florida Cancer Specialists If the patient prefers to avoid chemotherapy and h...
Medical Oncologist at University of Nebraska Medical Center Yes. If the patient prefers to avoid chemotherapy,...
Medical Oncologist at Allegheny Health Network Have a patient with a history of early-stage ER/He...
Medical Oncologist at University of Iowa Holden Comprehensive Cancer Center I would consider the CLEOPATRA regimen (taxane, tr...
Medical Oncologist at University of Nebraska Medical Center I agree with @Praveen Vikas. If this patient had n...
If the patient prefers to avoid chemotherapy and h...
Yes. If the patient prefers to avoid chemotherapy,...
Have a patient with a history of early-stage ER/He...
I would consider the CLEOPATRA regimen (taxane, tr...
I agree with @Praveen Vikas. If this patient had n...